Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Primary presentation and clinical course of pediatric and adolescent patients with differentiated thyroid carcinoma after radioiodine therapy.
Burgard C, Zacherl MJ, Todica A, Hornung J, Grawe F, Pekrul I, Zimmermann P, Schmid-Tannwald C, Ladurner R, Krenz D, Trupka A, Wagner J, Bartenstein P, Spitzweg C, Wenter V. Burgard C, et al. Among authors: spitzweg c. Front Oncol. 2023 Oct 2;13:1237472. doi: 10.3389/fonc.2023.1237472. eCollection 2023. Front Oncol. 2023. PMID: 37849815 Free PMC article.
Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE.
Eschbach RS, Hofmann M, Späth L, Sheikh GT, Delker A, Lindner S, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Tiling R, Brendel M, Wenter V, Dekorsy FJ, Zacherl MJ, Todica A, Ilhan H, Grawe F, Cyran CC, Unterrainer M, Rübenthaler J, Knösel T, Paul T, Boeck S, Westphalen CB, Spitzweg C, Auernhammer CJ, Bartenstein P, Unterrainer LM, Beyer L. Eschbach RS, et al. Among authors: spitzweg c. Front Oncol. 2023 Jan 30;13:992316. doi: 10.3389/fonc.2023.992316. eCollection 2023. Front Oncol. 2023. PMID: 36793617 Free PMC article.
Diagnostic accuracy of SSR-PET/CT compared to histopathology in the identification of liver metastases from well-differentiated neuroendocrine tumors.
Fabritius MP, Soltani V, Cyran CC, Ricke J, Bartenstein P, Auernhammer CJ, Spitzweg C, Schnitzer ML, Ebner R, Mansournia S, Hinterberger A, Lohse A, Sheikh GT, Winkelmann M, Knösel T, Ingenerf M, Schmid-Tannwald C, Kunz WG, Rübenthaler J, Grawe F. Fabritius MP, et al. Among authors: spitzweg c. Cancer Imaging. 2023 Sep 28;23(1):92. doi: 10.1186/s40644-023-00614-2. Cancer Imaging. 2023. PMID: 37770958 Free PMC article.
Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients.
Grawe F, Ebner R, Geyer T, Beyer L, Winkelmann M, Sheikh GT, Eschbach R, Schmid-Tannwald C, Cyran CC, Ricke J, Bartenstein P, Heimer MM, Faggioni L, Spitzweg C, Fabritius MP, Auernhammer CJ, Ruebenthaler J. Grawe F, et al. Among authors: spitzweg c. Eur Radiol. 2023 May;33(5):3416-3424. doi: 10.1007/s00330-023-09518-y. Epub 2023 Mar 25. Eur Radiol. 2023. PMID: 36964768 Free PMC article.
NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer.
Koehler VF, Achterfeld J, Sandner N, Koch C, Wiegmann JP, Ivanyi P, Käsmann L, Pusch R, Wolf D, Chirica M, Knösel T, Demes MC, Kumbrink J, Vogl TJ, Meyer G, Spitzweg C, Bojunga J, Kroiss M. Koehler VF, et al. Among authors: spitzweg c. J Cancer Res Clin Oncol. 2023 Nov;149(15):14035-14043. doi: 10.1007/s00432-023-05134-x. Epub 2023 Aug 7. J Cancer Res Clin Oncol. 2023. PMID: 37548775 Free PMC article.
PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE - first clinical experiences.
Kunte SC, Wenter V, Toms J, Lindner S, Unterrainer M, Eilsberger F, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Tiling MW, Sheikh GT, Mehrens D, Brendel M, Rübenthaler J, Auernhammer CJ, Spitzweg C, Unterrainer LM, Holzgreve A. Kunte SC, et al. Among authors: spitzweg c. Eur J Nucl Med Mol Imaging. 2024 Oct 15. doi: 10.1007/s00259-024-06944-y. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 39404789
Validation of the standardization framework SSTR-RADS 1.0 for neuroendocrine tumors using the novel SSTR‑targeting peptide [18F]SiTATE.
Ebner R, Lohse A, Fabritius MP, Rübenthaler J, Wängler C, Wängler B, Schirrmacher R, Völter F, Schmid HP, Unterrainer LM, Öcal O, Hinterberger A, Spitzweg C, Auernhammer CJ, Geyer T, Ricke J, Bartenstein P, Holzgreve A, Grawe F. Ebner R, et al. Among authors: spitzweg c. Eur Radiol. 2024 Nov;34(11):7222-7232. doi: 10.1007/s00330-024-10788-3. Epub 2024 May 20. Eur Radiol. 2024. PMID: 38769164 Free PMC article.
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Hadoux J, et al. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870969 Clinical Trial.
193 results